| 1.47 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.73 | 1-year : | 1.75 |
| Resists | First : | 1.48 | Second : | 1.49 |
| Pivot price | 1.47 | |||
| Supports | First : | 1.47 | Second : | 1.22 |
| MAs | MA(5) : | 1.47 | MA(20) : | 1.47 |
| MA(100) : | 1.47 | MA(250) : | 1.47  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 60.7 | |||
| 52-week | High : | 3.59 | Low : | 0.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EPZM ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.45 - 1.46 | 1.46 - 1.47 |
| Close: | 1.46 - 1.47 | 1.47 - 1.48 |
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Sat, 13 Apr 2024
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Movies UK
Tue, 03 May 2022
What Kind Of Shareholders Own Epizyme, Inc. (NASDAQ:EPZM)? - Yahoo Movies UK
Wed, 02 Mar 2022
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag - Yahoo Finance
Thu, 03 Feb 2022
Why Shares of Epizyme Soared 32.1% This Week - The Globe and Mail
Thu, 27 Jan 2022
Epizyme Announces Pricing of Public Offering of Common Stock - Business Wire
Sat, 11 Dec 2021
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company's SETD2 Inhibitor, EZM0414, at the ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 133 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 90.3 (%) |
| Shares Short | 5,490 (K) |
| Shares Short P.Month | 10,390 (K) |
| EPS | -2.3 |
| EPS Est Next Qtrly | -0.68 |
| EPS Est This Year | -2.36 |
| EPS Est Next Year | -2.45 |
| Book Value (p.s.) | 1.46 |
| Profit Margin | 0 % |
| Operating Margin | -582.2 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -352.4 % |
| Qtrly Rev. Growth | 14 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | -0.1 |
| Price to Book value | 1 |
| Price to Sales | 3.96 |
| Price to Cash Flow | -0.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|